Production (Stage)
Bolt Biotherapeutics, Inc.
BOLT
$5.64
-$0.13-2.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.12% | 10.99% | 6.65% | -17.38% | 36.33% |
| Total Depreciation and Amortization | -12.88% | -8.78% | -4.76% | -0.22% | -1.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -59.50% | 39.46% | -22.44% | 43.32% | -12.85% |
| Change in Net Operating Assets | 57.93% | -177.71% | 78.53% | 242.47% | 8.55% |
| Cash from Operations | 20.21% | -1.16% | 16.62% | -6.82% | 28.41% |
| Capital Expenditure | -- | 100.00% | 75.15% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 33.18% | -22.66% | 32.82% | 32.26% | -64.81% |
| Cash from Investing | 42.61% | -22.63% | 35.39% | 32.57% | -64.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -72.64% | -- | -46.26% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -72.64% | -- | -46.26% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.11% | -231.45% | 177.54% | 240.07% | -217.10% |